Christina Fuchs
Psychiatric/Mental Health · Hillsboro, ORNPI 1487014296
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2021 at $397 and has fallen 60.7% since, to $156 in 2025.
Across 51 payments — averaging $27.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$386
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$179
- Supernus Pharmaceuticals, Inc.$166
- Neurocrine Biosciences, Inc.$128
- Alkermes, Inc.$126
- Axsome Therapeutics, Inc.$89
- plus $313 from 8 others
What the payments were for
- Food & beverage$1,31195%
- Education$765%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $386 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $179 |
| Supernus Pharmaceuticals, Inc. | 8 | $166 |
| Neurocrine Biosciences, Inc. | 3 | $128 |
| Alkermes, Inc. | 1 | $126 |
| Axsome Therapeutics, Inc. | 1 | $89 |
| Sunovion Pharmaceuticals Inc. | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Teva Pharmaceuticals USA, Inc. | 1 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| USWM, LLC | 1 | $29 |
| Lundbeck LLC | 1 | $16 |
| Orexo US, Inc. | 1 | $12 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,387 in reported general payments places this provider in the 85th percentile of 540 psychiatric/mental health providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 62 | $390,604 |
| IngrezzaValbenazine Tosylate | 35 | $286,440 |
| VraylarCariprazine Hcl | 161 | $230,448 |
| CaplytaLumateperone Tosylate | 119 | $178,019 |
| Austedo XrDeutetrabenazine | 34 | $166,478 |
| Invega SustennaPaliperidone Palmitate | 30 | $87,027 |
| NuedextaDextromethorphan Hbr/Quinidine | 55 | $83,869 |
| RexultiBrexpiprazole | 40 | $60,972 |
| AristadaAripiprazole Lauroxil | 14 | $44,363 |
| TrintellixVortioxetine Hydrobromide | 80 | $38,561 |
| QelbreeViloxazine Hcl | 40 | $28,265 |
| BelsomraSuvorexant | 45 | $20,511 |
| VyvanseLisdexamfetamine Dimesylate | 37 | $14,232 |
| Aripiprazole | 174 | $10,791 |
| Divalproex Sodium ErDivalproex Sodium | 130 | $8,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $50 | $557,08196 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $128 | $286,44035 claims |
| AbbVieVraylar | $386 | $230,448161 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $179 | $178,019119 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $71 | $60,97240 claims |
| Alkermes, Inc.Aristada | $126 | $44,36314 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $166 | $28,26540 claims |
| Almatica Pharma LLCSertraline Hcl | $12 | $1,930137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 540 psychiatric/mental health providers in Oregon.
Other psychiatric/mental health in Hillsboro
- Amber HobergHillsboro$1.9M
- Carmen KosicekHillsboro$539K
- Crystal HigbeHillsboro$5K
- Shannon EatonHillsboro$2K
- Tina Matthews-HayesPortland$787K
- Johnni CanslerPortland$529K
- Jill CarterPortland$416K
- William BettsEugene$41K
- Michelle VoegelsPortland$29K
- Rance SmithKlamath Falls$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.